L. S. Khamraeva, N. K. Latipova, D. U. Narzullaeva
{"title":"Clinical efficacy of individual intraocular lens calculation in children with congenital cataract at risk of abnormal refraction","authors":"L. S. Khamraeva, N. K. Latipova, D. U. Narzullaeva","doi":"10.21516/2072-0076-2023-16-1-101-106","DOIUrl":null,"url":null,"abstract":"Purpose. To assess the clinical efficacy of the SRK II formula with a correction factor Rm in children with congenital cataracts who are at risk of pseudophakic myopia. Material and methods. A complex examination of 48 children (86 eyes) with congenital cataracts involved visometrics, tonometry, tonography, biomicroscopy, keratorefractometry, ophthalmoscopy, ultrasonography, and pachymetry. To determine the IOL power, we used the SRK II formula supplemented with the individual correction factor Rm, proposed by the authors. The examined children were divided into 2 groups. The main group 1 included 22 patients (42 eyes), for which the IOL power was calculated with the Rm factor. The control group 2 consisted of 26 patients (44 eyes) for which the IOL power was calculated according to the traditional SRK II formula using age-related hypocorrection of refraction but without the Rm coefficient. Results. The correction factor Rm, allowed us to achieve the targeted refraction in children who were at risk of developing pseudophakic myopia in 83.3 % of cases of the main group (versus 45.4 % of the control group cases) and reduce the development of high age-related refraction) by 37.9 %. In children of the main group, visual acuity reached, on average, 0.5 ± 0.001, while in the control group it was also higher but only reached 0.200 ± 0.001. Conclusion. The method of calculating the IOL optical power involving an individual correction factor Rm, according to the formula: SRK II – R – Rm can be recommended for clinical practice focused on children at risk of abnormal refractogenesis.","PeriodicalId":36080,"journal":{"name":"Rossiiskii Oftal''mologicheskii Zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rossiiskii Oftal''mologicheskii Zhurnal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21516/2072-0076-2023-16-1-101-106","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose. To assess the clinical efficacy of the SRK II formula with a correction factor Rm in children with congenital cataracts who are at risk of pseudophakic myopia. Material and methods. A complex examination of 48 children (86 eyes) with congenital cataracts involved visometrics, tonometry, tonography, biomicroscopy, keratorefractometry, ophthalmoscopy, ultrasonography, and pachymetry. To determine the IOL power, we used the SRK II formula supplemented with the individual correction factor Rm, proposed by the authors. The examined children were divided into 2 groups. The main group 1 included 22 patients (42 eyes), for which the IOL power was calculated with the Rm factor. The control group 2 consisted of 26 patients (44 eyes) for which the IOL power was calculated according to the traditional SRK II formula using age-related hypocorrection of refraction but without the Rm coefficient. Results. The correction factor Rm, allowed us to achieve the targeted refraction in children who were at risk of developing pseudophakic myopia in 83.3 % of cases of the main group (versus 45.4 % of the control group cases) and reduce the development of high age-related refraction) by 37.9 %. In children of the main group, visual acuity reached, on average, 0.5 ± 0.001, while in the control group it was also higher but only reached 0.200 ± 0.001. Conclusion. The method of calculating the IOL optical power involving an individual correction factor Rm, according to the formula: SRK II – R – Rm can be recommended for clinical practice focused on children at risk of abnormal refractogenesis.